Helping patients find the lung cancer
resources they deserve
How do we help lung cancer patients?
Massive Bio offers an independent cancer treatment analysis as well as free clinical trial matching for lung cancer patients. Our patient advocates work closely with patients to gather information on their current medical status, and then will provide a list of options from available cancer clinical trials close to your home.
We can also provide a comprehensive case analysis through our Virtual Tumor Board from cancer specialists. The Virtual Tumor Board (VTB) is comprised of highly specialized oncologists from nationally-recognized Cancer Centers of Excellence. In just 7-10 days after receiving your medical records, we can get you a treatment plan without having to travel far distances and use your valuable time.
There are approximately 737 lung cancer clinical trials that are currently recruiting patients in the United States right now. With such an extensive list, many of them could be beneficial for you. Our team of patient advocates, who are oncology nurses, and our artificial intelligence based clinical trial matching system will find the best option for you.
You may qualify for the following active clinical trials:
REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer.
With just a few clicks, you can see your clinical trial matches now. Click here to use our advanced clinical trial match tool.
Lung Cancer Facts
Lung cancer is known to be one of the most deadly types of cancer. Only 18.6% of lung cancer patients survive five years. Not only one of the hardest types of cancer to treat, but also the most popular. There are 2.1 million new cases worldwide and 1.8 million deaths annually.
The two subtypes are small cell and non-small cell lung cancer. Non-small cell accounts for 85% of all patients and small cell accounts for 15%. The main difference between the two subtypes is the size of the cancer cells.
95% of small cell lung cancer patients have a history of smoking.
The biggest contributor and most well known risk factor is smoking. Smoking cigarettes and being exposed to smoke (Secondhand Smoke) directly lead to lung cancer. Other risk factors include being exposed to radiation, asbestos, tar, air pollution, and any other toxin that is commonly known to be harmful.
Photodynamic therapy (PDT)
Watching & Waiting
Low-dose CT scans are the most common form of screening for lung cancer. Using small amounts of radiation, the scans are used to detect cancer as small as a grain of rice. X-rays used to be the primary form of screening but they can only detect cancer the size of a dime.
Lung cancer is the leading cause of death by cancer for men and women. Despite being responsible for the most cancer deaths, it is only the 4th most popular cancer type. For cases discovered before the cancer has metastasized, the 5-year survival rate is 56%. If the cancer has already spread, the 5-year survival rate is only 5%. These numbers are discouraging when only 16% of cases are discovered at an early stage.
What is Non-Small Cell Lung Cancer?
Non-small cell lung cancer (NSCLC) make up about 80-85% of lung cancers. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
How Can Non-Small Cell Lung Cancer Patients With MET Mutation Be Treated?
Treatment for NSCLC can include surgery, chemotherapy, immunotherapy and targeted therapy. Targeted therapy works by targeting or interfering with the proteins that control the cancer. There are many targeted therapy drugs already approved for NSCLC, but research is ongoing to find more proteins to target.
The MET protein is one of the newer targets for NSCLC treatment. It is a tyrosine kinase receptor and is found to be altered in 3-4% of lung cancer patients. The MET pathway is thought to be the primary driving mechanism, particularly MET exon 14 alterations and MET gene amplification in NSCLC.
REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer is a clinical trial that is studying a new drug targeting MET exon 14 gene mutations, MET gene amplification, and MET protein expression in NSCLC. Massive Bio can help you understand whether you would qualify for this trial or other trials for lung cancer.
What Is Small Cell Lung Cancer?
Small cell lung cancer (SCLC) make up about 10-15% of lung cancers. This type is more aggressive and tends to respond well to chemotherapy and radiation therapy. The main subtypes of SCLC are Small cell carcinoma (oat cell cancer) and combined small cell carcinoma.
Our team of patient advocates can help guide you to treatment options you might not have been previously aware of. Although you might be new to cancer, we certainly are not. Navigating cancer patients through the tricky path of finding the best treatment is our goal. No two cancer patients are alike, which is why we find treatment for all of our patients based on their specific genomics, location, stage of cancer, and nearly 100 more data points.